BioGaia (BIOG-B.ST) Stock Analysis & AI Equity Report
BioGaia (BIOG-B.ST) overview
BioGaia (BIOG-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, BioGaia reported revenue of SEK 1,538m and operating profit of SEK 412m; the year-end share price was 106.20 SEK and market capitalisation was SEK 10,743m. BioGaia is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get BioGaia's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-18. Data will be refreshed during report generation.
About BioGaia
BioGaia AB is a Swedish healthcare company that develops, manufactures, markets and sells probiotic products based on L. reuteri strains. Its portfolio covers gut, immune and oral health for babies, children and adults, with products sold through distribution partners and subsidiaries in more than 100 countries.
Generate the BioGaia report
BioGaia is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for BioGaia and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.